LEADER 2: Baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: Preliminary observations

Diabetes, Obesity and Metabolism

Volumn 17, Issue 5, 2015, Pages 477-486

  Daniels, G H ^a   Hegedus L ^b   Marso, S P ^c   Nauck, M A ^d   Zinman, B ^e   Bergenstal, R M ^f   Mann, J F E ^g   Derving Karsbol J ^h   Moses, A C ^h   Buse, J B ⁱ   Tuttle, R M ^j  

^a HARVARD MEDICAL SCHOOL   (United States)

^b ODENSE UNIVERSITY HOSPITAL   (Denmark)

^c UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^d Diabeteszentrum   (Germany)

^e MOUNT SINAI HOSPITAL   (Canada)

^f INTERNATIONAL DIABETES CENTER   (United States)

^g UNIVERSITY OF ERLANGEN NUREMBERG   (Germany)

^h NOVO NORDISK A S   (Denmark)

ⁱ UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^j MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

more..

Author keywords

C cell disease; Calcitonin; Diabetes; Incretins

Indexed keywords

CALCITONIN; LIRAGLUTIDE; PLACEBO; ANTIDIABETIC AGENT;

ADULT; ARTICLE; BODY MASS; CALCITONIN BLOOD LEVEL; CARDIOVASCULAR RISK; CONTROLLED STUDY; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; NON INSULIN DEPENDENT DIABETES MELLITUS; RANDOMIZED CONTROLLED TRIAL; SEX DIFFERENCE; AGED; BLOOD; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOUBLE BLIND PROCEDURE; MIDDLE AGED; PATHOPHYSIOLOGY; STATISTICAL MODEL;

AGED; BODY MASS INDEX; CALCITONIN; CARDIOVASCULAR DISEASES; DIABETES MELLITUS, TYPE 2; DOUBLE-BLIND METHOD; FEMALE; GLOMERULAR FILTRATION RATE; HUMANS; HYPOGLYCEMIC AGENTS; LINEAR MODELS; LIRAGLUTIDE; MALE; MIDDLE AGED; SEX FACTORS;

EID: 84926195839     PISSN: 14628902     EISSN: 14631326     Source Type: Journal    
DOI: 10.1111/dom.12444     Document Type: Article

References (25)

1. Garber A, Henry R, Ratner R et al. Liraglutide versus glimepiride monotherapy for type 2 diabetes (LEAD-3 Mono): a randomised, 52-week, phase III, double-blind, parallel-treatment trial. Lancet 2009; 373: 473-481.
2. Buse JB, Rosenstock J, Sesti G et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009; 374: 39-47.
3. Bjerre Knudsen L, Madsen LW, Andersen S et al. Glucagon-like peptide-1 receptor agonists activate rodent thyroid C-cells causing calcitonin release and C-cell proliferation. Endocrinology 2010; 151: 1473-1486.
4. Madsen LW, Knauf JA, Gotfredsen C et al. GLP-1 receptor agonists and the thyroid: C-cell effects in mice are mediated via the GLP-1 receptor and not associated with RET activation. Endocrinology 2012; 153: 1538-1547.
5. Hegedus L, Moses AC, Zdravkovic M, Le Thi T, Daniels GH. GLP-1 and calcitonin concentration in humans: lack of evidence of calcitonin release from sequential screening in over 5000 subjects with type 2 diabetes or nondiabetic obese subjects treated with the human GLP-1 analog, liraglutide. J Clin Endocrinol Metab 2011; 96: 853-860.
6. Costante G, Durante C, Francis Z, Schlumberger M, Filetti S. Determination of calcitonin levels in C-cell disease: clinical interest and potential pitfalls. Nat Clin Pract Endocrinol Metab 2009; 5: 35-44.
7. d'Herbomez M, Caron P, Bauters C et al. Reference range of serum calcitonin levels in humans: influence of calcitonin assays, sex, age, and cigarette smoking. Eur J Endocrinol 2007; 157: 749-755.
8. Costante G, Meringolo D, Durante C et al. Predictive value of serum calcitonin levels for preoperative diagnosis of medullary thyroid carcinoma in a cohort of 5817 consecutive patients with thyroid nodules. J Clin Endocrinol Metab 2007; 92: 450-455.
9. Hasselgren M, Hegedus L, Godballe C, Bonnema SJ. Benefit of measuring basal serum calcitonin to detect medullary thyroid carcinoma in a Danish population with a high prevalence of thyroid nodules. Head Neck 2010; 32: 612-618.
10. Hegedus L. Clinical practice. The thyroid nodule. N Engl J Med 2004; 351: 1764-1771.
11. Cooper DS, Doherty GM, Haugen BR et al. Revised American Thyroid Association management guidelines for patients with thyroid nodules and differentiated thyroid cancer. Thyroid 2009; 19: 1167-1214.
12. Daniels GH. Screening for medullary thyroid carcinoma with serum calcitonin measurements in patients with thyroid nodules in the United States and Canada. Thyroid 2011; 21: 1199-1207.
13. Gharib H, Papini E, Paschke R, Duick DS, Valcavi R, Hegedus L. American Association of Clinical Endocrinologists, Associazione Medici Endocrinologi, and European Thyroid Association Medical guidelines for clinical practice for the diagnosis and management of thyroid nodules. Endocr Pract 2010; 16(Suppl. 1): 1-43.
14. Paschke R, Hegedus L, Alexander E, Valcavi R, Papini E, Gharib H. Thyroid nodule guidelines: agreement, disagreement and need for future research. Nat Rev Endocrinol 2011; 7: 354-361.
15. Marso SP, Poulter NR, Nissen SE et al. Design of the liraglutide effect and action in diabetes: evaluation of cardiovascular outcome results (LEADER) trial. Am Heart J 2013; 166: 823-830, E825.
16. Guyetant S, Rousselet MC, Durigon M et al. Sex-related C cell hyperplasia in the normal human thyroid: a quantitative autopsy study. J Clin Endocrinol Metab 1997; 82: 42-47.
17. Lissak B, Baudin E, Cohen R et al. Pentagastrin testing in patients with renal insufficiency: normal responsivity of mature calcitonin. Thyroid 1998; 8: 265-268.
18. Kanbay M, Wolf M, Selcoki Y et al. Association of serum calcitonin with coronary artery disease in individuals with and without chronic kidney disease. Int Urol Nephrol 2012; 44: 1169-1175.
19. Niccoli P, Brunet P, Roubicek C et al. Abnormal calcitonin basal levels and pentagastrin response in patients with chronic renal failure on maintenance hemodialysis. Eur J Endocrinol 1995; 132: 75-81.
20. Akan B, Bohmig G, Sunder-Plassmann G, Borchhardt KA. Prevalence of hypercalcitoninemia in patients on maintenance dialysis referred to kidney transplantation. Clin Nephrol 2009; 71: 538-542.
21. Healton CG, Vallone D, McCausland KL, Xiao H, Green MP. Smoking, obesity, and their co-occurrence in the United States: cross sectional analysis. BMJ 2006; 333: 25-26.
22. Erdogan MF, Gursoy A, Kulaksizoglu M. Long-term effects of elevated gastrin levels on calcitonin secretion. J Endocrinol Invest 2006; 29: 771-775.
23. Zayed AA, Alzubaidi M, Atallah S, Momani MS, Al-Delaimy WK. Should Food Intake and Circadian Rhythm be Considered When Measuring Serum Calcitonin Level? Endocr Pract 2013; 19: 620-626.
24. Giovanella L, Suriano S. Spurious hypercalcitoninemia and heterophilic antibodies in patients with thyroid nodules. Head Neck 2011; 33: 95-97.
25. Rosario PW, Calsolari MR. Influence of chronic autoimmune thyroiditis and papillary thyroid cancer on serum calcitonin levels. Thyroid 2013; 23: 671-674.